Saldívar-Rodea CA, Guerrero-Avendaño GM, Benítez-Barradas MI, Reyes- Caldelas MÁ

Language: Spanish
References: 15
Page: 279-293
PDF size: 885.26 Kb.

ABSTRACT

Introduction: gliomas represent approximately 77% of malignant primary brain tumors. In astrocytic tumors, grade I corresponds to astrocytoma, grade II to diffuse and pilomyxoid astrocytomas, grade III to anaplastic astrocytoma, and grade IV to glioblastoma. Magnetic resonance is highly useful in diagnosis, classification, and treatment of patients with astrocytic tumors.
Objetive: evaluate the degree of correlation between image studies and histopathological findings.
Material and Method: a retrospective study from 2013 through 2015, in which 25 patients were included. All the patients had histopathological or anatomopathological confirmation. Of the 25 patients in the study, 12 were diagnosed by magnetic resonance as astrocytic tumors, 10 as tumors of different histological strains, 2 cases as abscesses, and 1 as intraparenchymal hemorrhage.
Results: of the 12 patients diagnosed generically as astrocytic tumors, 4 were assigned the correct histological grade. We can group the radiological diagnoses issued in three main groups: 1) astrocytic tumors; 2) tumors of histological strain different from astrocytomas, and 3) lesions of non-neoplastic etiology. Analyzing the results of the study underscored the need to standardize and validate both the magnetic resonance protocol and medical-radiological reporting.
Conclusion: we propose the idea of improving reliability and interpretation by developing image acquisition and (structured radiological interpretation protocols) which reduce interobserver variability.

REFERENCES

1. Margaret W, Yuriko M, Terri C, et al. Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro-Oncology 2002:278-299.

2. Judith AS, James LF, Kenneth DA et al. Epidemiology and molecular pathology of glioma. Nature Clinical Practice 2006;2(9):494 -503.

3. David NL, Hiroko O, Otmar D, et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol 2007;114:97-109.

4. David NL, Arie P, Guido R, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neurophatol 2016;131: 803-820.

5. Ranjith G, Parvathy R, Vikas V, et al. Machine learning methods for the classification of gliomas: Initial results using features extracted from MR spectroscopy. Neuroradiol J. 2015;28(2):106-11.

6. Shuichi H, Xia Y, Toshihiro K, et al. Malignant Astrocytic Tumors: Clinical Importance of Apparent Diffusion Coefficient in Prediction of Grade and Prognosis. RSNA Radiology 2006;241(3):839-846.

7. Jayashree KC, Elizabeth RG, Kyrre EE, et al. Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma. Cancer Res 2014;74(17):4622– 4637.

8. Jain KK, Sahoo P, Tyagi R, et al. Prospective glioma grading using single-dose dynamic contrast-enhanced perfusion MRI. Clinical Radiology;70(10):1128-1135.

9. Min ZG, Liu HJ, Li M, et al. Accuracy of MR perfusion weighted imaging for cerebral glioma grading: a metaanalysis. Zhonghua Yi Xue Za Zhi 2010;90(41):2927-31.

10. Mabray MC, Cohen BA, Villanueva-Meyer JE, et al. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. AJR Am J Roentgenol 2015;205(5):1075–1085.

11. Cheng HT, Kuo-Chen W, Chen-Nen C, et al. Differentiation of Brain Abscesses from Glioblastomas and Metastatic Brain Tumors: Comparisons of Diagnostic Performance of Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging before and after Mathematic Contrast Leakage Correction. PLoS One 2014;9(10): e109172.

12. Bohman L, Swanson KR, Moore JL, et al. Magnetic resonance imaging characteristics of glioblastoma multiforme: implications for understanding glioma ontogeny. Neurosurgery. 2010 Nov;67(5):1319-27.

13. Wu CX, Lin GS, Lin Z, et al. Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastoma. World J Surg Oncol 2015;13:97.

14. Reardon DA, Ballman KV, Buckner JC, et al. Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro Oncol.2014;16(l 7): 24-35.

15. Lambron J, Rakotonjanahary J, Loisel D, et al. Can we improve accuracy and reliability of MRI interpretation in children with optic pathway glioma? Proposal for a reproducible imaging classification. Neuroradiology 2016;58(2):197-208.